Notably, the combined expression of CCR9, CCL25, CD8A, and CD8B genes in tumors positively correlated with a higher DSS probability in patients with melanoma, with a better hazard ratio (HR) and P value compared to the expression of CD8A and CD8B genes only (Fig. 7A). This evidence concerns the gene CCL25 and melanoma.